June 18, 2021 11:09 AM EDT

FDA's controversial Aduhelm decision leaves ALS patients feeling spurned

Max Gelman

Senior Editor

The FDA’s controversial approval of Biogen’s Aduhelm drug for Alzheimer’s disease has been met with fierce resistance from all corners of the biopharma industry, but …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

FDA's controversial Aduhelm decision leaves ALS patients feeling spurned

Max Gelman

Senior Editor

Sign up to read this article for free.

Takeda to pay $200M for rights to anemia drug from Keros

Revolution sells $600M in shares on back of RAS inhibitor portfolio updates

Janux soars on early prostate cancer data that could challenge Novartis' Pluvicto

Ipsen secures rights to preclinical T cell engager in $610M pact with French biotech

Roche teams up with Chicago autoimmune biotech COUR Pharmaceuticals

Gilead makes another ADC move, inking up to $415M pact with Tubulis

FDA's con­tro­ver­sial Aduhelm de­ci­sion leaves ALS pa­tients feel­ing spurned

Max Gelman

Senior Editor

Sign up to read this article for free.

more like this

Take­da to pay $200M for rights to ane­mia drug from Keros

Rev­o­lu­tion sells $600M in shares on back of RAS in­hibitor port­fo­lio up­dates

Janux soars on ear­ly prostate can­cer da­ta that could chal­lenge No­var­tis' Plu­vic­to

Ipsen se­cures rights to pre­clin­i­cal T cell en­gager in $610M pact with French biotech

Roche teams up with Chica­go au­toim­mune biotech COUR Phar­ma­ceu­ti­cals

Gilead makes an­oth­er ADC move, ink­ing up to $415M pact with Tubu­lis

FDA's controversial Aduhelm decision leaves ALS patients feeling spurned

Takeda to pay $200M for rights to anemia drug from Keros

Revolution sells $600M in shares on back of RAS inhibitor portfolio updates

Janux soars on early prostate cancer data that could challenge Novartis' Pluvicto

Ipsen secures rights to preclinical T cell engager in $610M pact with French biotech

Roche teams up with Chicago autoimmune biotech COUR Pharmaceuticals

Gilead makes another ADC move, inking up to $415M pact with Tubulis